SCHEMBL10270063

SCHEMBL10270063

Cc1nc(-c2cccs2)ccc1C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.55
ALDH1A1 P00352 9/20 0.52
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
HPGD P15428 6/20 0.52
MAPT P10636 5/20 0.52
TDP1 Q9NUW8 4/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
RAB9A P51151 7/20 0.47
NPC1 O15118 5/20 0.47
HSD17B10 Q99714 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.43
GAA P10253 4/20 0.43
GLA P06280 2/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
USP2 O75604 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20232427 0.80 KDM4E (0.63) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL12454616 0.76 KDM4E (0.62) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL25510512 0.73 RPS6KB2 (0.41) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL820477 0.73 KDM4E (0.55) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL8257857 0.72 KDM4E (0.66) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL15165636 0.72 MAPT (0.57) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL18134403 0.72 ALDH1A1 (0.51) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL4428914 0.71 KDM4E (1.00) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL25547019 0.70 RAB9A (0.61) KDM4EALDH1A1MEN1KMT2AHPGD
SCHEMBL16438246 0.70 KDM4E (0.71) KDM4EALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180153859-A1 METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE T3D THERAPEUTICS, INC. (US) 2018-06-07 US disclosed
US-20120141483-A1 METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES DARA BIOSCIENCES, INC. 2012-06-07 US disclosed
US-20110152330-A1 INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION LOWE DEREK B 2011-06-23 US disclosed
US-20110065129-A1 INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION LOWE DEREK B 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152330-A1 INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION INSR, ACACA, IAPP KDM4E 3156/4885ALDH1A1 51/4885MEN1 1522/4885
US-20180153859-A1 METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE CHRNA2, ACACA, CHAT KDM4E 4364/4885ALDH1A1 164/4885MEN1 2982/4885
US-20110065129-A1 INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION INSR, ACACA, IAPP KDM4E 3156/4885ALDH1A1 51/4885MEN1 1522/4885
US-20120141483-A1 METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES APP, MAPT, TNF KDM4E 4069/4885ALDH1A1 109/4885MEN1 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.